Pneumocystis pneumonia in patients with rheumatic diseases receiving prolonged, non-high-dose steroids-clinical implication of primary prophylaxis using trimethoprim-sulfamethoxazole.

Jun Won ParkJeffrey R CurtisMin Jung KimHajeong LeeYeong Wook SongEun Bong Lee

Published in: Arthritis research & therapy (2019)

Incidence of PCP in patients with rheumatic diseases receiving prolonged, medium-dose steroids depends on the presence of risk factors. Prophylactic TMP-SMX may have greater benefit than potential risk in the high-risk subgroup.

Keyphrases

risk factors
high dose
low dose
stem cell transplantation
clinical trial
human health
phase iii
risk assessment
intensive care unit
study protocol
acute respiratory distress syndrome